Internationalisation and Health Care Export S. von Bandemer University of Applied Sciences, Gelsenkirchen Institute Work and Technology, Science Park

Transcription

1 Internationalisation and Health Care Export S. von Bandemer University of Applied Sciences, Gelsenkirchen Institute Work and Technology, Science Park Content Why Internationalisation? Why Health Care Export? Foreign patient in Germany Clincial Studies motor for the health sector world-wide International demand development Consequences for Internationalisation and Health Care Export

2 Internationalisation and Health Care Export S. von Bandemer and W. Breipohl Why Internationalisation? Initial facts Starting with: Guest patients in Germany International Research and Clinical Studies System solutions in Health Economy International Staff Development Modications of Health Systems Parameters of success and sustainability in Health Care Export

3 Why Health Care Export? Initial Facts Only about 0,3 % of the patients treated are coming from abroad (living there) Only 2-3 % of patients world-wide are treated in Germany Only 7-8 % of world-wide Health Care Spending are created in Germany Research, Innovative Developments, Education and Service in the Health Care Sector (the economic motor in contemporary industrialized countries) must be oreinted along with world-wide demands

4 Foreign patients in Germany Internationalisierung von Gesundheitsdienstleistungen Patientenimport und Serviceexport Institut Arbeit und Technik, Gelsenkirchen Sozial- und Seniorenwirtschaftszentrum GmbH, Gelsenkirchen VVA Health Marketing GmbH, Essen Gefördert durch das Bundesministerium für Bildung und Forschung Förderungszeitraum: Import of patients 2004 Ranking between states State Numbers % NRW ,35 Bayern ,45 Baden-Württemberg ,30 Hessen ,26 Saarland ,36 Niedersachsen ,20 Rheinland-Pfalz ,36 Berlin ,21 Schleswig-Holstein ,36 Hamburg 908 0,20 Brandenburg 869 0,17 Sachsen 675 0,36 Bremen 575 0,29 Thüringen 508 0,36 Sachsen-Anhalt 437 0,36 Mecklenburg-Vorpommern 396 0,10

5 Foreign patients in Germany migration of patients to:

6 Foreign patients in Germany Internationalisierung von Gesundheitsdienstleistungen Patientenimport und Serviceexport Institut Arbeit und Technik, Gelsenkirchen Sozial- und Seniorenwirtschaftszentrum GmbH, Gelsenkirchen VVA Health Marketing GmbH, Essen Gefördert durch das Bundesministerium für Bildung und Forschung Förderungszeitraum: Contries of origin total Focus in border regions Patients from Gulf States preferentially in München (706) Aachen (378), Heidelberg (230), Bonn (149) Hamburg (134).

7 Foreign patients in Germany Chancens and limitations in attracting patients from abroad Within those foreign patients less than 2/5 are elective patients Global strategies to attract foreign patients so far are still only rudimental or side-product of tourism Attraction of foreign patients can be planned Chances exist in trans-border service structures To improve, systematic research, educational curricula and unique health care service offers are required which take into account cultural sensitivity Simple commercialisation strategies without respecting e.g. UN MDGs, WHO policies, one world concepts and socio-ecological balance will soon become counter productive

8 Clinical Studies International Health Sector Research is furiously growing Clinical studies are essentiell in international competivitiy Clinical studies allow financing a major part of clincially relevant research Participation in clinical studies leads to early involve-ment and sustain cooperation and marketing contacts via new procedures, products and their implementations Clincial studies guarantee patients an early benefit of innovation

9 Clinical Studies Distribution of clinical studies world-wide (n=60.000) US are in the lead India und China together meanwhile bypass Germany in the number of clinical studies Increase of clinical study numbers was 60% in 2007

10 Clinical Studies Clinical studies in Europe Germany in the lead European market is widely fragmented Lack in European harmonisation weakens the growth potential and international competivity

11 Clinical studies in Paediatrics world-wide

12 Clinical studies in European Paediatrics (middle of 2008) National markets are often too small for sound clincial studies

13 Clinical studies Potential in international clinical studies Clinical studies will in crease in world regions with growing markets (India, China,...) Faster inclusion of sufficient numbers of patients over there and thus acceleration of innovation Cooperation of European Study and Education Centres with respective partners in Emerging Markets to assure participation in growing markets Sicherung der Beteiligung am medizinisch-technischen Fortschritt und dessen Refinanzierung

14 International demand development Growth potential and international demand Maximal growth potential in Health Economy is linked to the international demand development (health care service included) Demand has to be met with holistic solutions (prediction, prevention, diagnosis, therapy, rehabilitation, monitoring, supply organisation, integrated process solutions) Innovation at home can be financed by international market strategies Sole commercial strategies will not lead to sustain developments International strategies to be parallel to national demand devlopments (e.g. demography) Health sector development strategies in response to societal demands (e.g. complementary medicine) National and internationl developments in reflection of UN, WHO, One World, Global Marshall Plan etc.

15 International demand development Internationalisierung von Gesundheitsdienstleistungen Patientenimport und Serviceexport Institut Arbeit und Technik, Gelsenkirchen Sozial- und Seniorenwirtschaftszentrum GmbH, Gelsenkirchen VVA Health Marketing GmbH, Essen Gefördert durch das Bundesministerium für Bildung und Forschung Förderungszeitraum:

16 International demand development Expenses for Diabetes treatment Germany versus world-wide World-wide expenses in diabetes treatment will amount to 30fold the German figure in 2025 Refinancing of required innovation in diagnostics and therapy do require global strategies Quelle: World Diabetes Foundation 2003, Köster u.a. 2005

17 International demand development 2050 about 80 % of stroke patients will occur in todays developing and industrially emerging countries

18 International demand development Value chain in stroke health care - Prevention - Emergency Resuce Management - Emergency Hospital Units - Stroke Units - Normal Units - Rehabilitation - Follow Up Monitoring and Care - Permanent Care Harmonisation between all above chain componentsfor the benefit of patients Synergy between all above increases instituional growth potential Close relation with new products and quality of life

19 International demand development Strokes in India (Prediction and) Prevention for 1 Million stroke candidates per year Creation and running of 2000 Stroke-Units to reach German service standards Lysis therapies with a market value of in Indian price settings

20 International demand development Diabetes in India by about 2020 Prevention and treatment of 75 million diabetes patients 1% of renale decompenation means dialyses 1% renal transplantation means per year

21 Consequences for Internationalisation and Health Care Export Creation of research and cooperation networks for mutual win-win realisation of participating partners and their clients Sufficient qualification and advice solutions to implement local service units and structures Joint running of service units/offers in form of cultural sensitive systemic/holistic solutions Integration and development of such solutions as autonom units in/to Centers and Hospitals Specific efforts with curricula, vocational training, health service offers Involvement of new EC member and candidate countries Beyond Europe strategies Synergy between international concepts, cultural approaches and visions

22 Consequences for Internationalisation and Health Care Export Appropriate international fine-tunig organisation of (Public) Health Systems Current tendency to major heterogenity in the financing of (Public) Health System solutions with high demand (private renumeration and rudimentary public health service offers) Variation in national and cultural tradition regarding health insurance (limited solidarity solutions) Formation of cooperation networks with health service educators, trainers, trainee associations and suppliers for dissemination

23 Consequences for Internationalisation and Health Care Export Need for the stipulation of international (Public/Private) Health Systems Transfer of European Health System solutions will not prevail without cultural sensitivity and specifications Potential of private financing is more accentuated in countries with emerging markets than in Europe World-wide existence of multiple non harmonzed local/island solutions Potential of undermining for WHO, UN etc. policies with lack of intransparency in financing

24 Consequences for Internationalisation and Health Care Export Establishment of national and international Health Regions Coordination / harmonisation of / between education, training, LLL, service and supply networks for systemic / holistic solutions Harmonisation of national and international mobilities on the basis of respective qualification frames (Bologna, Lisbon, European Qualification Frame) Cultural sensitive cooperation in the development of market and concept developments and taking into account international WHO, UN, Global Marshall plan etc. policies and visions Definiton of the label: Health made in Europe (European Health System Development and Organisation)

25 Consequences for Internationalisation and Health Care Export Globalisation a must Etablishment of a globally accepted label / healkth product Close liaison with local players / local and international player Integration of complete value chain under win-win policies Flexible adaptation of best practice Emerging Market strategies

26 Thank you for your audience Stephan von Bandemer Winrich Breipohl Munscheidstr Gelsenkirchen Tel. 0209/